<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Vet Med Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Vet. Med. Sci</journal-id>
      <journal-id journal-id-type="publisher-id">JVMS</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Veterinary Medical Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0916-7250</issn>
      <issn pub-type="epub">1347-7439</issn>
      <publisher>
        <publisher-name>The Japanese Society of Veterinary Science</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26074249</article-id>
      <article-id pub-id-type="pmc">4667679</article-id>
      <article-id pub-id-type="publisher-id">15-0096</article-id>
      <article-id pub-id-type="doi">10.1292/jvms.15-0096</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinical Pathology</subject>
          <subj-group>
            <subject>Note</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors
with a c-<italic>kit</italic> mutation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>IRIE</surname>
            <given-names>Mitsuhiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref rid="cor1" ref-type="corresp">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>TAKEUCHI</surname>
            <given-names>Yoshinori</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>OHTAKE</surname>
            <given-names>Yuzo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>SUZUKI</surname>
            <given-names>Hitomi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>NAGATA</surname>
            <given-names>Nao</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MIYOSHI</surname>
            <given-names>Takuma</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>KAGAWA</surname>
            <given-names>Yumiko</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>YAMAGAMI</surname>
            <given-names>Tetsushi</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <aff id="aff1"><label>1)</label>Shikoku Veterinary Medical Center, 3308&#x2013;5 Ikenobe, Miki-cho,
Kita-gun, Kagawa 761&#x2013;0701, Japan</aff>
        <aff id="aff2"><label>2)</label>Department of Veterinary Internal Medicine, Graduate School
of Agricultural and Life Sciences, The University of Tokyo, 1&#x2013;1&#x2013;1 Yayoi, Bunkyo-ku, Tokyo
113&#x2013;8657, Japan</aff>
        <aff id="aff3"><label>3)</label>North Labo, 8&#x2013;35 2-chome-kita, Hongo, Shiroishi-ku,
Sapporo-shi, Hokkaido 003&#x2013;0027, Japan</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>*</label>Correspondence to: Irie, M., Shikoku Veterinary Medical
Center, 3308&#x2013;5 Ikenobe, Miki-cho, Kita-gun, Kagawa 761&#x2013;0701, Japan. e-mail: <email xlink:href="mac@vet.ne.jp">mac@vet.ne.jp</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2015</year>
      </pub-date>
      <volume>77</volume>
      <issue>11</issue>
      <fpage>1535</fpage>
      <lpage>1539</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>2</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>6</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2015 The Japanese Society of Veterinary Science</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p>
        </license>
      </permissions>
      <abstract>
        <p>A 13-year-old spayed mixed-breed dog was diagnosed with a gastrointestinal
stromal tumor (GIST) after histopathological examination of an abdominal mass. Five months
after surgical resection of the tumor, we detected the recurrence of GIST with multiple
disseminated abdominal lesions. A sequence analysis of cDNA obtained from a biopsy of the
recurrent tumors revealed a mutation within exon 9 of the c<italic>-kit</italic> gene
(1523A&gt;T, Asn<sup>508</sup>Ile), which has been shown to cause ligand-independent
phosphorylation of the KIT protein in GISTs and canine mast cell tumors (MCTs). Upon
detection of the recurrent tumors, we initiated treatment with imatinib mesylate (10
mg/kg, q 24 hr). After 2 months, the dog achieved complete remission. Our findings
indicate that canine GIST, and possibly MCT, may be responsive to molecular-targeted
therapy.</p>
      </abstract>
      <kwd-group>
        <kwd>canine</kwd>
        <kwd>gastrointestinal stromal tumor</kwd>
        <kwd>imatinib mesylate</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Gastrointestinal stromal tumors (GISTs) occur in humans, dogs and other species, and are
among the most common mesenchymal tumors that originate from the interstitial cells of Cajal
in the walls of the gastrointestinal tract [<xref rid="r14" ref-type="bibr">14</xref>, <xref rid="r15" ref-type="bibr">15</xref>].</p>
    <p>The c<italic>-kit</italic> gene encodes the KIT protein, which is a receptor tyrosine kinase
that mediates the signaling of stem cell factor (SCF), a cytokine involved in hematopoiesis
and mast cell growth [<xref rid="r12" ref-type="bibr">12</xref>].Mutations of the
c<italic>-kit</italic> gene have been identified in exons 9 (5&#x2013;10%) and 11 (60&#x2013;70%) in cases
of human GISTs [<xref rid="r1" ref-type="bibr">1</xref>]. Studies on human GISTs [<xref rid="r3" ref-type="bibr">3</xref>] and canine mast cell tumors (MCTs) [<xref rid="r7" ref-type="bibr">7</xref>] have indicated that imatinib mesylate, a tyrosine kinase inhibitor, may
be effective in the treatment of these tumors, depending on the presence and location of
c<italic>-kit</italic> mutations [<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r9" ref-type="bibr">9</xref>]. Furthermore, a previous case study has reported imatinib
mesylate to be effective against canine GISTs that contained a mutation in exon 11 of the
c<italic>-kit</italic> gene [<xref rid="r9" ref-type="bibr">9</xref>]. Cases of canine GISTs
with c<italic>-kit</italic> mutations may therefore be clinically responsive to imatinib
mesylate treatment [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r6" ref-type="bibr">6</xref>].</p>
    <p>Here, we describe a case of canine recurrent GIST harboring a mutation in exon 9 of the
c<italic>-kit</italic> gene that responded clinically to the administration of imatinib
mesylate.</p>
    <p>A 13-year-old, 10-kg, spayed mixed-breed dog with a body condition score of 3/5 and a 1-week
history of vomiting and anorexia was referred to the Shikoku Veterinary Medical Center,
located in Kagawa Prefecture, Japan. Upon physical examination, we detected a large mass in
the abdominal cavity through palpation. Abdominal ultrasonography revealed the mass to be
approximately 10 cm in diameter with mixed echogenicity. A fine-needle aspiration of the mass
showed clusters of spindle-shaped cells. There were no apparent abnormalities observed in the
complete blood cell count, blood chemistry tests or blood coagulation profile.</p>
    <p>Abdominal radiography, however, revealed the presence of a single large lesion in the
abdominal cavity. Based on computed tomography (CT) findings (<xref ref-type="fig" rid="fig_001">Fig. 1A and 1B</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>Preoperative CT images: (A) Transverse image of the 5th lumbar vertebra and (B)
sagittal image indicating a large mass with an irregular surface (12 &#xD7; 8 &#xD7; 6 cm in size)
extending from the cecum. (C) Photograph of the surgically resected area showing the
main tumor and multiple disseminated masses (arrows) in the omentum. L5, 5th lumbar
vertebra; m, main tumor; s, spleen; b, bladder.</p></caption><graphic xlink:href="jvms-77-1535-g001"/></fig>), we concluded that the mass originated from the cecum and could be surgically
resected. Laparotomy exposed a tumor that was approximately 12 &#xD7; 8 &#xD7; 6 cm in size, had an
irregular surface and originated from the cecum (<xref ref-type="fig" rid="fig_001">Fig.
1C</xref>). In addition to the large mass, we observed 5 to 10 smaller masses (ranging from
1 mm to 20 mm in diameter) in the omentum. During surgery, the cecum was partially removed,
and the omentum with the disseminated tumors was excised.</p>
    <p>Histopathological examination of the excised tumor revealed that the mass had unclear
boundaries and had originated from the muscle layer of the cecum. The tumor tissue was
composed of spindle-form neoplastic cells arranged in streams and interlacing bundles, and was
supported by abundant basophilic myxoid stroma. The tumor cells had wispy eosinophilic
cytoplasm, as well as ovoid to cigar-shaped nuclei with a single small nucleolus (<xref ref-type="fig" rid="fig_002">Fig. 2A</xref><fig orientation="portrait" fig-type="figure" id="fig_002" position="float"><label>Fig. 2.</label><caption><p>(A) Histopathological features of the resected abdominal mass using hematoxylin and
eosin stain at 100 &#xD7; magnification. Tumors were composed of spindle-form neoplastic
cells arranged in streams and interlacing bundles and were supported by abundant
basophilic myxoid stroma. (B) Histopathological features of the resected abdominal mass
using hematoxylin and eosin stain at 400 &#xD7; magnification. The tumor cells showed wispy
eosinophilic cytoplasm, ovoid to cigar-shaped nuclei with a small single nucleolus, and
mild to moderate anisocytosis and anisokaryosis. (C) Immunohistochemical analysis of the
resected abdominal mass using immunohistochemical staining with anti-KIT antibodies
followed by hematoxylin counterstain at 100 &#xD7; magnification. Most cells were positive
for human KIT.</p></caption><graphic xlink:href="jvms-77-1535-g002"/></fig>). Mild to moderate anisocytosis and anisokaryosis were also observed in the tumor
cells. The mitotic index ranged from 0 to 1 mitotic figures per 5 high-power fields (<xref ref-type="fig" rid="fig_002">Fig. 2B</xref>).</p>
    <p>Immunohistochemical analysis using an antibody against human KIT (Dako, Carpinteria, CA,
U.S.A.) demonstrated that most of the tumor cells were positive for KIT proteins (<xref ref-type="fig" rid="fig_002">Fig. 2C</xref>), and the tumor was therefore identified as
GIST. A DNA sample obtained from paraffin-embedded sections of the tumor was subjected to
sequence analysis of exon 11 of the c-<italic>kit</italic> gene; however, no mutations were
found in the target sequence.</p>
    <p>Because several residual tumors were detected in the omentum, 200 mg/m<sup>2</sup> of
carboplatin (Paraplatin; Bristol-Myers Squibb, New York, NY, U.S.A.) was administered to the
dog 2 weeks after surgery; the drug was further administered once every 3 weeks for a total of
6 doses. However, a scheduled follow-up examination conducted 160 days after the initial
surgery indicated the possible recurrence of GIST in the omentum. CT scans showed the presence
of numerous masses with diameters ranging from 2 cm to 5 cm. Exploratory laparotomy revealed
multiple tumors up to 5 cm in diameter. As the complete and safe removal of all the tumors was
not feasible, only a limited number of masses were resected for biopsy. Histopathological
examination of the resected masses confirmed the recurrence of GIST.</p>
    <p>Total RNA was extracted from paraffin-embedded tumor tissue resected during the second
surgery using an RNeasy FFPE kit (Qiagen, Valencia, CA, U.S.A.), and the corresponding cDNA
was synthesized as previously described [<xref rid="r16" ref-type="bibr">16</xref>]. The
forward primer 5&#x2032;-GCACAGACACAGAGTAATAGC-3&#x2032; and reverse primer 5&#x2032;-GAAGGCACCAGCACCCAAAGT-3&#x2032; were
then used to amplify c<italic>-kit</italic> cDNA from the single-strand cDNA through PCR with
KOD FX DNA polymerase (Toyobo, Osaka, Japan). The PCR products were sub-cloned into a
pCR-Blunt vector (Invitrogen, Carlsbad, CA, U.S.A.), and the sequence of the full length
c<italic>-kit</italic> cDNA was obtained using a previously described method [<xref rid="r16" ref-type="bibr">16</xref>]. When compared with the wild-type canine
c-<italic>kit</italic> gene (GenBank accession no. AY313776), the GIST tissue showed a point
mutation in exon 9 (1523A&gt;T) (<xref ref-type="fig" rid="fig_003">Fig. 3</xref><fig orientation="portrait" fig-type="figure" id="fig_003" position="float"><label>Fig. 3.</label><caption><p>Identification of the point mutation in the c-<italic>kit</italic> gene and assembly of
wild-type and mutant c<italic>-kit</italic> nucleotide sequences. D1 to D5,
immunoglobulin-like domains; TM, transmembrane domain; JM, juxtamembrane domain; TK1,
adenosine triphosphate (ATP) binding site; TK2, activation loop.</p></caption><graphic xlink:href="jvms-77-1535-g003"/></fig>).</p>
    <p>Based on the findings of the c<italic>-kit</italic> sequence analysis, we began
administration of imatinib mesylate (10 mg/kg q 24 hr) (Veenat; Natco Pharma, Hyderabad,
India) 2 weeks after surgery. In an abdominal ultrasonography conducted 2 weeks after the
initial imatinib mesylate administration, the lengths of the residual masses in the abdominal
cavity were found to have shrunk to less than half of their original lengths. In accordance
with the classification criteria for solid tumor response evaluation [<xref rid="r4" ref-type="bibr">4</xref>], the observed reduction in tumor size indicated a partial remission (PR).
Two months after the initiation of imatinib mesylate treatment, ultrasonography and CT imaging
indicated complete remission (CR) of GIST (<xref ref-type="fig" rid="fig_004">Fig.
4</xref><fig orientation="portrait" fig-type="figure" id="fig_004" position="float"><label>Fig. 4.</label><caption><p>CT images taken after the recurrence of GIST: (A) Transverse image and (B) frontal
image of the abdomen taken 162 days after the initial surgery. The white arrowheads
indicate the intraabdominal mass. (C) Transverse image and (D) frontal image of the
abdomen taken 1,700 days after the initial surgery. The mass was observed to have
completely disappeared in this later stage. s, spleen; rk, right kidney.</p></caption><graphic xlink:href="jvms-77-1535-g004"/></fig>). Treatment of imatinib mesylate with the same dosage was continued even after
achievement of CR to prevent further recurrence. The dog remained in CR with continuous daily
administration of imatinib mesylate. Ultrasonography was conducted during periodic health
examinations once every 3&#x2013;6 months.</p>
    <p>Although the dog was periodically re-examined at our veterinary medical center, it eventually
died of pneumonia 4 years and 5 months after the second surgery. There was no indication of
GIST recurrence at the time of the dog&#x2019;s death.</p>
    <p>This case did not present with any severe adverse events associated with imatinib mesylate
treatment. All of the procedures involved in the examination and treatment of this case were
conducted in accordance with the guidelines for small animal practice issued by the Japanese
Veterinary Medical Association in 2007.</p>
    <p>A mutation within exon 9 of the c<italic>-kit</italic> gene (1523A&gt;T) was found in the
GIST tissue extracted from our canine patient. Although the phosphorylation of the KIT protein
was not evaluated in this study, this type of mutation has been observed in 1.5% of canine
MCTs [<xref rid="r11" ref-type="bibr">11</xref>] and has been shown to cause constitutive
phosphorylation of the KIT protein [<xref rid="r17" ref-type="bibr">17</xref>].</p>
    <p>The c<italic>-kit</italic> point mutation (1523A&gt;T) observed in this case has yet to be
reported in canine GISTs. Kobayashi <italic>et al.</italic> [<xref rid="r9" ref-type="bibr">9</xref>] have previously reported a case of canine GIST harboring a c<italic>-kit</italic>
mutation in exon 11 that responded to imatinib mesylate treatment [<xref rid="r8" ref-type="bibr">8</xref>]; although imatinib mesylate treatment was able to generate a PR response,
CR could not be achieved in their canine patient. In contrast, the canine patient described
here achieved CR with the same dose of imatinib mesylate (10 mg/kg q 24 hr) and survived for a
long period after treatment without relapse. Although a further study is needed to produce
definitive results, our findings in conjunction with the report by Kobayashi <italic>et
al.</italic> [<xref rid="r9" ref-type="bibr">9</xref>] suggest the possible effectiveness of
imatinib mesylate for the treatment of GISTs in dogs.</p>
    <p>As human GIST patients with exon 9 or exon 11 mutations in the <italic>c-kit</italic> gene
have been shown to be responsive to imatinib mesylate treatment [<xref rid="r2" ref-type="bibr">2</xref>], this has become the first-choice drug in the treatment of metastatic or
recurrent GISTs. However, patients with exon 9 mutations have been reported to have decreased
sensitivity to this treatment [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r3" ref-type="bibr">3</xref>]. Therefore, such patients require higher doses of imatinib mesylate, or
even treatment with other tyrosine kinase inhibitors, such as sunitinib malate. Despite having
an exon 9 c-<italic>kit</italic> mutation, our canine patient demonstrated good response to
imatinib mesylate treatment and was able to achieve CR. This apparent discrepancy may be
explained in part by the difference in the type of exon 9 mutation between canine (point
mutation) and human (duplication) GISTs. It has been documented that the responsiveness of
human GISTs to anticancer drugs can be affected by differences in the types of
c<italic>-kit</italic> mutations [<xref rid="r1" ref-type="bibr">1</xref>].</p>
    <p>Although our canine patient remained in CR during the follow-up period, we decided to provide
long-term administration of imatinib mesylate to prevent further recurrence. Several studies
have suggested that the long-term administration of imatinib mesylate may lead to the
emergence of drug-resistant clones in the treatment of advanced GISTs in humans [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r8" ref-type="bibr">8</xref>, <xref rid="r13" ref-type="bibr">13</xref>]. On the other hand, Le Cesne <italic>et al</italic>.
have advocated non-interrupted imatinib mesylate treatment for advanced human GISTs unless
adverse effects are evident [<xref rid="r10" ref-type="bibr">10</xref>]. As our patient did
not develop any severe adverse events during the treatment, we decided to continue the
administration of imatinib mesylate.</p>
    <p>In this case study, the administration of imatinib mesylate was found to be an effective
treatment in a canine patient with GISTs that contained an exon 9 mutation in the
c<italic>-kit</italic> gene. Molecular-targeted therapy may therefore be a promising
therapeutic strategy for GISTs in dogs.</p>
  </body>
  <back>
    <ack>
      <p>We would like to thank Professor Hajime Tsujimoto from the Department of
Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The
University of Tokyo, for his advice in the preparation of this manuscript. None of the
authors have any financial relationships with individuals or organizations that could
inappropriately influence or bias the content of the study.</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Corless</surname><given-names>C. L.</given-names></name><name><surname>Barnett</surname><given-names>C. M.</given-names></name><name><surname>Heinrich</surname><given-names>M. C.</given-names></name></person-group><year>2011</year>. <article-title>Gastrointestinal stromal tumours: origin
and molecular oncology</article-title>. <source><italic>Nat. Rev.
Cancer</italic></source><volume>11</volume>: <fpage>865</fpage>&#x2013;<lpage>878</lpage>.
<pub-id pub-id-type="pmid">22089421</pub-id></mixed-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Debiec-Rychter</surname><given-names>M.</given-names></name><name><surname>Wasag</surname><given-names>B.</given-names></name><name><surname>Stul</surname><given-names>M.</given-names></name><name><surname>De Wever</surname><given-names>I.</given-names></name><name><surname>Van Oosterom</surname><given-names>A.</given-names></name><name><surname>Hagemeijer</surname><given-names>A.</given-names></name></person-group><year>2004</year>. <article-title>Gastrointestinal stromal tumours (GISTs)
negative for KIT (CD117 antigen) immunoreactivity</article-title>. <source><italic>J.
Pathol.</italic></source><volume>202</volume>: <fpage>430</fpage>&#x2013;<lpage>438</lpage>.
doi: <pub-id pub-id-type="doi">10.1002/path.1546</pub-id><pub-id pub-id-type="pmid">15095270</pub-id></mixed-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>de Silva</surname><given-names>C. M.</given-names></name><name><surname>Reid</surname><given-names>R.</given-names></name></person-group><year>2003</year>. <article-title>Gastrointestinal stromal tumors(GIST):
C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy
with imatinib</article-title>. <source><italic>Pathol. Oncol.
Res.</italic></source><volume>9</volume>: <fpage>13</fpage>&#x2013;<lpage>19</lpage>. doi:
<pub-id pub-id-type="doi">10.1007/BF03033708</pub-id><pub-id pub-id-type="pmid">12704441</pub-id></mixed-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Eisenhauer</surname><given-names>E. A.</given-names></name><name><surname>Therasse</surname><given-names>P.</given-names></name><name><surname>Bogaerts</surname><given-names>J.</given-names></name><name><surname>Schwartz</surname><given-names>L. H.</given-names></name><name><surname>Sargent</surname><given-names>D.</given-names></name><name><surname>Ford</surname><given-names>R.</given-names></name><name><surname>Dancey</surname><given-names>J.</given-names></name><name><surname>Arbuck</surname><given-names>S.</given-names></name><name><surname>Gwyther</surname><given-names>S.</given-names></name><name><surname>Mooner</surname><given-names>M.</given-names></name><name><surname>Rubinstein</surname><given-names>L.</given-names></name><name><surname>Shankar</surname><given-names>L.</given-names></name><name><surname>Dodd</surname><given-names>L.</given-names></name><name><surname>Kaplan</surname><given-names>R.</given-names></name><name><surname>Lacombe</surname><given-names>D.</given-names></name><name><surname>Verwell</surname><given-names>J.</given-names></name></person-group><year>2009</year>. <article-title>New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1)</article-title>. <source><italic>Eur. J.
Cancer</italic></source><volume>45</volume>: <fpage>228</fpage>&#x2013;<lpage>247</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Frost</surname><given-names>D.</given-names></name><name><surname>Lasota</surname><given-names>J.</given-names></name><name><surname>Miettinen</surname><given-names>M.</given-names></name></person-group><year>2003</year>. <article-title>Gastrointestinal stromal tumors and
leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic
study of 50 cases</article-title>. <source><italic>Vet.
Pathol.</italic></source><volume>40</volume>: <fpage>42</fpage>&#x2013;<lpage>54</lpage>. doi:
<pub-id pub-id-type="doi">10.1354/vp.40-1-42</pub-id><pub-id pub-id-type="pmid">12627712</pub-id></mixed-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Gregory-Bryson</surname><given-names>E.</given-names></name><name><surname>Bartlett</surname><given-names>E.</given-names></name><name><surname>Kiupel</surname><given-names>M.</given-names></name><name><surname>Hayes</surname><given-names>S.</given-names></name><name><surname>Yuzbasiyan-Gurkan</surname><given-names>V.</given-names></name></person-group><year>2010</year>. <article-title>Canine and human gastrointestinal stromal
tumors display similar mutations in c-KIT exon 11</article-title>. <source><italic>BMC
Cancer</italic></source><volume>10</volume>: <fpage>559</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2407-10-559</pub-id><pub-id pub-id-type="pmid">20950418</pub-id></mixed-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Isotani</surname><given-names>M.</given-names></name><name><surname>Ishida</surname><given-names>N.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name><name><surname>Tamura</surname><given-names>K.</given-names></name><name><surname>Yagihara</surname><given-names>H.</given-names></name><name><surname>Ochi</surname><given-names>S.</given-names></name><name><surname>Kato</surname><given-names>R.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Fujita</surname><given-names>M.</given-names></name><name><surname>Fujino</surname><given-names>Y.</given-names></name><name><surname>Setoguchi</surname><given-names>A.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Washizu</surname><given-names>T.</given-names></name><name><surname>Bonkobara</surname><given-names>M.</given-names></name></person-group><year>2008</year>. <article-title>Effect of tyrosine kinase inhibition by
imatinib mesylate on mast cell tumors in dogs</article-title>. <source><italic>J. Vet.
Intern. Med.</italic></source><volume>22</volume>:
<fpage>985</fpage>&#x2013;<lpage>988</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1939-1676.2008.00132.x</pub-id><pub-id pub-id-type="pmid">18564222</pub-id></mixed-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Joensuu</surname><given-names>H.</given-names></name><name><surname>Hohenberger</surname><given-names>P.</given-names></name><name><surname>Corless</surname><given-names>C. L.</given-names></name></person-group><year>2013</year>. <article-title>Gastrointestinal stromal
tumour</article-title>. <source><italic>Lancet</italic></source><volume>382</volume>:
<fpage>973</fpage>&#x2013;<lpage>983</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60106-3</pub-id><pub-id pub-id-type="pmid">23623056</pub-id></mixed-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kobayashi</surname><given-names>M.</given-names></name><name><surname>Kuroki</surname><given-names>S.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Yasuda</surname><given-names>A.</given-names></name><name><surname>Sawada</surname><given-names>H.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Washizu</surname><given-names>T.</given-names></name><name><surname>Bonkobara</surname><given-names>M.</given-names></name></person-group><year>2013</year>. <article-title>Imatinib-associated tumour response in a
dog with a non-resectable gastrointestinal stromal tumour harbouring a
c-<italic>kit</italic> exon 11 deletion mutation</article-title>. <source><italic>Vet.
J.</italic></source><volume>198</volume>: <fpage>271</fpage>&#x2013;<lpage>274</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.tvjl.2013.05.035</pub-id><pub-id pub-id-type="pmid">23820134</pub-id></mixed-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Le Cesne</surname><given-names>A.</given-names></name><name><surname>Ray-Coquard</surname><given-names>I.</given-names></name><name><surname>Bui</surname><given-names>B. N.</given-names></name><name><surname>Adenis</surname><given-names>A.</given-names></name><name><surname>Rios</surname><given-names>M.</given-names></name><name><surname>Bertucci</surname><given-names>F.</given-names></name><name><surname>Chevreau</surname><given-names>C.</given-names></name><name><surname>Cupissol</surname><given-names>D.</given-names></name><name><surname>Cioffi</surname><given-names>A.</given-names></name><name><surname>Chabaud</surname><given-names>S.</given-names></name><name><surname>Perol</surname><given-names>D.</given-names></name><name><surname>Blay</surname><given-names>J. Y.</given-names></name></person-group>, French Sarcoma Group<year>2010</year>. <article-title>Discontinuation of
imatinib in patient with advanced gastrointestinal stromal tumours after 3 years of
treatment: an open-label multicenter randomized phase 3 trial</article-title>.
<source><italic>Lancet Oncol.</italic></source><volume>11</volume>:
<fpage>942</fpage>&#x2013;<lpage>949</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(10)70222-9</pub-id><pub-id pub-id-type="pmid">20864406</pub-id></mixed-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Letard</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Hanssens</surname><given-names>K.</given-names></name><name><surname>Palmerini</surname><given-names>F.</given-names></name><name><surname>Leventhal</surname><given-names>P. S.</given-names></name><name><surname>Guery</surname><given-names>S.</given-names></name><name><surname>Moussy</surname><given-names>A.</given-names></name><name><surname>Kinet</surname><given-names>J. P.</given-names></name><name><surname>Hermine</surname><given-names>O.</given-names></name><name><surname>Dubreuil</surname><given-names>P.</given-names></name></person-group><year>2008</year>. <article-title>Gain-of-function mutations in the
extracellular domain of KIT are common in canine mast cell tumors</article-title>.
<source><italic>Mol. Cancer Res.</italic></source><volume>6</volume>:
<fpage>1137</fpage>&#x2013;<lpage>1145</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-08-0067</pub-id><pub-id pub-id-type="pmid">18644978</pub-id></mixed-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Li</surname><given-names>S. Q.</given-names></name><name><surname>O&#x2019;Leary</surname><given-names>T. J.</given-names></name><name><surname>Sobin</surname><given-names>L. H.</given-names></name><name><surname>Erozan</surname><given-names>Y. S.</given-names></name><name><surname>Rosenthal</surname><given-names>D. L.</given-names></name><name><surname>Przygodzki</surname><given-names>R. M.</given-names></name></person-group><year>2000</year>. <article-title>Analysis of KIT mutation and protein
expression in fine needle aspirates of gastrointestinal stromal/smooth muscle
tumors</article-title>. <source><italic>Acta
Cytol.</italic></source><volume>44</volume>: <fpage>981</fpage>&#x2013;<lpage>986</lpage>. doi:
<pub-id pub-id-type="doi">10.1159/000328620</pub-id><pub-id pub-id-type="pmid">11127756</pub-id></mixed-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Nishida</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Miyazaki</surname><given-names>Y.</given-names></name></person-group><year>2009</year>. <article-title>Gastrointestinal stromal tumor; a bridge
between bench and bedside</article-title>. <source><italic>Gastric
Cancer</italic></source><volume>12</volume>: <fpage>175</fpage>&#x2013;<lpage>188</lpage>. doi:
<pub-id pub-id-type="doi">10.1007/s10120-009-0525-8</pub-id><pub-id pub-id-type="pmid">20047122</pub-id></mixed-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Russell</surname><given-names>K. N.</given-names></name><name><surname>Mehler</surname><given-names>S. J.</given-names></name><name><surname>Skorupski</surname><given-names>K. A.</given-names></name><name><surname>Baez</surname><given-names>J. L.</given-names></name><name><surname>Shofer</surname><given-names>F. S.</given-names></name><name><surname>Goldschmidt</surname><given-names>M. H.</given-names></name></person-group><year>2007</year>. <article-title>Clinical and immunohistochemical
differentiation of gastrointestinal stromal tumors from leiomyosarcomas in dogs: 42
cases (1990&#x2013;2003)</article-title>. <source><italic>J. Am. Vet. Med.
Assoc.</italic></source><volume>230</volume>: <fpage>1329</fpage>&#x2013;<lpage>1333</lpage>.
doi: <pub-id pub-id-type="doi">10.2460/javma.230.9.1329</pub-id><pub-id pub-id-type="pmid">17472558</pub-id></mixed-citation>
      </ref>
      <ref id="r15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Sarlomo-Rikala</surname><given-names>M.</given-names></name><name><surname>Kovatich</surname><given-names>A. J.</given-names></name></person-group><year>1998</year>. <article-title>CD117: a sensitive marker for
gastrointestinal stromal tumors that is more specific than CD34</article-title>.
<source><italic>Mod. Pathol.</italic></source><volume>11</volume>:
<fpage>728</fpage>&#x2013;<lpage>734</lpage>. <pub-id pub-id-type="pmid">9720500</pub-id></mixed-citation>
      </ref>
      <ref id="r16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Shirao</surname><given-names>K.</given-names></name><name><surname>Nishida</surname><given-names>T.</given-names></name><name><surname>Doi</surname><given-names>T.</given-names></name><name><surname>Komatsu</surname><given-names>Y.</given-names></name><name><surname>Muro</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ueda</surname><given-names>E.</given-names></name><name><surname>Ohtsu</surname><given-names>A.</given-names></name></person-group><year>2010</year>. <article-title>Phase I/II study of sunitinib malate in
Japanese patients with gastrointestinal stromal tumor after failure of prior treatment
with imatinib mesylate</article-title>. <source><italic>Invest. New
Drugs</italic></source><volume>28</volume>: <fpage>866</fpage>&#x2013;<lpage>875</lpage>. doi:
<pub-id pub-id-type="doi">10.1007/s10637-009-9306-9</pub-id><pub-id pub-id-type="pmid">19730791</pub-id></mixed-citation>
      </ref>
      <ref id="r17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Takeuchi</surname><given-names>Y.</given-names></name><name><surname>Fujino</surname><given-names>Y.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Nakagawa</surname><given-names>T.</given-names></name><name><surname>Ohno</surname><given-names>K.</given-names></name><name><surname>Sasaki</surname><given-names>N.</given-names></name><name><surname>Sugano</surname><given-names>S.</given-names></name><name><surname>Tsujimoto</surname><given-names>H.</given-names></name></person-group><year>2010</year>. <article-title>Aberrant autophosphorylation of
c-<italic>kit</italic> receptor in canine mast cell tumor cell lines</article-title>.
<source><italic>Vet. Immunol. Immunopathol.</italic></source><volume>137</volume>:
<fpage>208</fpage>&#x2013;<lpage>216</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetimm.2010.05.009</pub-id><pub-id pub-id-type="pmid">20591500</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
